NovaBay Files 8-K on Material Agreement; Details Undisclosed
Ticker: NBY · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1389545
| Field | Detail |
|---|---|
| Company | Novabay Pharmaceuticals, INC. (NBY) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: material-agreement, corporate-action, regulatory-filing
TL;DR
**NovaBay filed an 8-K about a material agreement, but gave no details, leaving investors in the dark.**
AI Summary
NovaBay Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, reporting an event on January 5, 2024, related to an 'Entry into a Material Definitive Agreement' and 'Other Events.' While the filing indicates a significant agreement, it does not disclose the specific details of the agreement or the parties involved. This lack of specific information could create uncertainty for investors, as the nature and impact of this material agreement on NovaBay's future operations and financial performance remain unknown, making it difficult to assess the stock's potential.
Why It Matters
The filing signals a potentially significant business development for NovaBay Pharmaceuticals, Inc., but the absence of details means investors can't evaluate its financial implications or strategic importance.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but provides no specifics, creating uncertainty about its potential positive or negative impact on the company.
Analyst Insight
A smart investor would hold off on making significant decisions until NovaBay Pharmaceuticals, Inc. provides more specific details about the 'Material Definitive Agreement' to assess its potential impact on the company's financials and future prospects.
Key Numbers
- 20240105 — Conformed Period of Report (The date of the earliest event reported in the 8-K filing.)
- 001-33678 — Commission File Number (NovaBay's SEC file number, indicating its registration status.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 5, 2024 (date) — date of the earliest event reported
- January 10, 2024 (date) — date the 8-K was filed
- NBY (company) — trading symbol for NovaBay Pharmaceuticals, Inc.
- NYSE American (company) — exchange where NovaBay's common stock is registered
- $0.01 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- NovaBay will release further details about the material definitive agreement within the next 30-60 days. (NovaBay Pharmaceuticals, Inc.) — medium confidence, target: 2024-03-10
- The lack of immediate detail will lead to short-term investor speculation regarding the nature of the agreement. (NBY stock price) — high confidence, target: 2024-01-24
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024, as stated under 'Date of earliest event reported: January 5, 2024'.
What specific items were reported in this 8-K filing by NovaBay Pharmaceuticals, Inc.?
NovaBay Pharmaceuticals, Inc. reported 'Entry into a Material Definitive Agreement' and 'Other Events' under the ITEM INFORMATION section of the filing.
What is the trading symbol and exchange for NovaBay Pharmaceuticals, Inc.'s common stock?
The trading symbol for NovaBay Pharmaceuticals, Inc.'s common stock is NBY, and it is registered on the NYSE American exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the par value of NovaBay Pharmaceuticals, Inc.'s common stock?
The par value of NovaBay Pharmaceuticals, Inc.'s common stock is $0.01 per share, as stated under 'Title of Each Class Common Stock, par value $0.01 per share'.
Where is NovaBay Pharmaceuticals, Inc.'s principal executive office located?
NovaBay Pharmaceuticals, Inc.'s principal executive office is located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608, according to the filing's business address.
Filing Stats: 797 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-01-10 08:00:12
Key Financial Figures
- $0.01 — h Registered Common Stock , par value $0.01 per share   NBY   NYSE
Filing Documents
- nby20240108_8k.htm (8-K) — 27KB
- ex_613183.htm (EX-10.1) — 59KB
- ex_613557.htm (EX-99.1) — 17KB
- logo01.jpg (GRAPHIC) — 9KB
- logo02.jpg (GRAPHIC) — 5KB
- 0001437749-24-001062.txt ( ) — 272KB
- nby-20240105.xsd (EX-101.SCH) — 3KB
- nby-20240105_def.xml (EX-101.DEF) — 11KB
- nby-20240105_lab.xml (EX-101.LAB) — 15KB
- nby-20240105_pre.xml (EX-101.PRE) — 11KB
- nby20240108_8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits.   (d) Exhibits.   Exhibit No. Description 10.1 License and Distribution Agreement by and between NovaBay and Sonoma, dated, January 5, 2024  99.1 Press release issued by NovaBay and Sonoma, dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)         Certain schedules and exhibits were omitted as well as certain confidential portions of the agreements by means of marking such portions with brackets (due to such confidential portions not being material and being competitively harmful if publicly disclosed) pursuant to Item 601 of Regulation S-K promulgated by the Securities and Exchange Commission. NovaBay agrees to supplementally furnish a copy of any omitted schedule, exhibit or confidential portions to the Securities and Exchange Commission upon request.        
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     NovaBay Pharmaceuticals, Inc.             By: /s/ Justin M. Hall       Justin M. Hall       Chief Executive Officer and General Counsel           Dated: January 10, 2024